CA3093976A1 - Kv7 channel activators compositions and methods of use - Google Patents
Kv7 channel activators compositions and methods of use Download PDFInfo
- Publication number
- CA3093976A1 CA3093976A1 CA3093976A CA3093976A CA3093976A1 CA 3093976 A1 CA3093976 A1 CA 3093976A1 CA 3093976 A CA3093976 A CA 3093976A CA 3093976 A CA3093976 A CA 3093976A CA 3093976 A1 CA3093976 A1 CA 3093976A1
- Authority
- CA
- Canada
- Prior art keywords
- stereoisomer
- disorder
- compound
- benzo
- neonatal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
- C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862644932P | 2018-03-19 | 2018-03-19 | |
| US201862644902P | 2018-03-19 | 2018-03-19 | |
| US62/644,932 | 2018-03-19 | ||
| US62/644,902 | 2018-03-19 | ||
| US201862663438P | 2018-04-27 | 2018-04-27 | |
| US62/663,438 | 2018-04-27 | ||
| US201862697198P | 2018-07-12 | 2018-07-12 | |
| US62/697,198 | 2018-07-12 | ||
| PCT/US2019/023039 WO2019183148A1 (en) | 2018-03-19 | 2019-03-19 | Kv7 channel activators compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3093976A1 true CA3093976A1 (en) | 2019-09-26 |
Family
ID=67905138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3093976A Pending CA3093976A1 (en) | 2018-03-19 | 2019-03-19 | Kv7 channel activators compositions and methods of use |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10851067B2 (enExample) |
| EP (1) | EP3768677A4 (enExample) |
| JP (2) | JP7757036B2 (enExample) |
| KR (3) | KR20250150168A (enExample) |
| CN (6) | CN119118926A (enExample) |
| AU (3) | AU2019239955B2 (enExample) |
| BR (1) | BR112020018933A2 (enExample) |
| CA (1) | CA3093976A1 (enExample) |
| IL (2) | IL277419B2 (enExample) |
| MX (2) | MX2020009693A (enExample) |
| SG (1) | SG11202008030WA (enExample) |
| WO (1) | WO2019183148A1 (enExample) |
| ZA (1) | ZA202308070B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2749103T3 (es) * | 2014-09-12 | 2020-03-19 | Knopp Biosciences Llc | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| CN119118926A (zh) * | 2018-03-19 | 2024-12-13 | 诺普生物科学有限责任公司 | Kv7通道激活剂组合物和使用方法 |
| IL328371A (en) * | 2019-09-17 | 2026-07-01 | Knopp Biosciences Llc | Usage methods for KV7 channel operators |
| WO2023133256A1 (en) * | 2022-01-07 | 2023-07-13 | Biohaven Therapeutics Ltd. | Pyrazolo[1,5-a]pyridin-2,3-yl amides as kv7 channel activators |
| WO2024050389A1 (en) * | 2022-08-30 | 2024-03-07 | Biohaven Therapeutics Ltd. | Combination therapies including metal channel activators and nmda receptor antagonists |
| EP4584250A4 (en) * | 2022-09-06 | 2026-02-25 | Biohaven Therapeutics Ltd | POLYTHERAPIES INCLUDING METAL CHANNEL ACTIVATORS |
| KR20260049605A (ko) * | 2023-08-10 | 2026-04-14 | 바이오하벤 테라퓨틱스 리미티드 | Kv7.2/7.3 칼륨 채널 활성제의 서방형 제형 |
| KR20260074334A (ko) * | 2023-09-15 | 2026-05-22 | 바이오하벤 테라퓨틱스 리미티드 | 강력하고 선택적인 칼륨 채널 활성제를 이용한 뇌전증 및 관련 질환의 치료 방법 |
| KR20260114565A (ko) * | 2023-11-15 | 2026-07-22 | 씨엠에스 리서치 앤드 디벨롭먼트 피티이. 리미티드 | 6,5-융합 헤테로아릴 유도체 및 이의 용도 |
| CN122421958A (zh) * | 2023-12-22 | 2026-07-17 | 拜奥海芬治疗学有限公司 | 神经性障碍的组合治疗 |
| WO2025198930A1 (en) * | 2024-03-18 | 2025-09-25 | Humanwell Pharmacuetical Us, Inc. | Small molecules as kcnq2/3 (kv7.2/3) channel activators and their medical use thereof |
| WO2026042005A1 (en) | 2024-08-18 | 2026-02-26 | Biohaven Therapeutics Ltd. | Prodrugs of benzimidazol-1,2-yl amide compounds |
| WO2026046157A1 (zh) * | 2024-08-27 | 2026-03-05 | 上海汇伦医药股份有限公司 | 苯并杂芳环类化合物、含其的组合物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0772181B2 (ja) | 1989-06-26 | 1995-08-02 | 株式会社大塚製薬工場 | ベンズイミダゾール誘導体 |
| JPH0772181A (ja) | 1993-09-03 | 1995-03-17 | Advantest Corp | 電位波形測定方法および装置 |
| GB9413724D0 (en) | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
| US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
| SE0301701D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
| CA2607219A1 (en) | 2005-05-18 | 2007-02-15 | Neuraxon, Inc. | Substituted benzimidazole compounds with dual nos inhibitory activity and mu opioid agonist activity |
| CN101516873A (zh) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | 用作钾通道调节剂的吲唑基衍生物 |
| US8288393B2 (en) | 2007-08-10 | 2012-10-16 | Nippon Soda Co., Ltd. | Nitrogen-containing heterocyclic compound and pest control agent |
| EP2218718A1 (en) | 2007-11-22 | 2010-08-18 | Zenyaku Kogyo Kabushikikaisha | Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same |
| GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
| US7820665B2 (en) | 2007-12-19 | 2010-10-26 | Amgen Inc. | Imidazopyridazine inhibitors of PI3 kinase for cancer treatment |
| US20110269783A1 (en) | 2008-11-10 | 2011-11-03 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| KR101685718B1 (ko) | 2008-12-19 | 2016-12-12 | 제넨테크, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
| US8883812B2 (en) | 2010-07-08 | 2014-11-11 | Pfizer Inc. | Piperidinyl pyrimidine amides as Kv7 potassium channel openers |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| WO2014145852A2 (en) * | 2013-03-15 | 2014-09-18 | Knopp Biosciences Llc | Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators |
| US10471139B2 (en) * | 2013-08-15 | 2019-11-12 | The University Of Kansas | Toll-like receptor agonists |
| ES2749103T3 (es) * | 2014-09-12 | 2020-03-19 | Knopp Biosciences Llc | Benzoimidazol-1,2-ilamidas como activadores del canal Kv7 |
| CN119118926A (zh) * | 2018-03-19 | 2024-12-13 | 诺普生物科学有限责任公司 | Kv7通道激活剂组合物和使用方法 |
| IL328371A (en) * | 2019-09-17 | 2026-07-01 | Knopp Biosciences Llc | Usage methods for KV7 channel operators |
-
2019
- 2019-03-19 CN CN202410805542.XA patent/CN119118926A/zh active Pending
- 2019-03-19 SG SG11202008030WA patent/SG11202008030WA/en unknown
- 2019-03-19 BR BR112020018933-2A patent/BR112020018933A2/pt unknown
- 2019-03-19 CN CN202410835028.0A patent/CN118955402A/zh active Pending
- 2019-03-19 AU AU2019239955A patent/AU2019239955B2/en active Active
- 2019-03-19 CN CN202410805545.3A patent/CN118955400A/zh active Pending
- 2019-03-19 IL IL277419A patent/IL277419B2/en unknown
- 2019-03-19 IL IL310136A patent/IL310136A/en unknown
- 2019-03-19 CN CN202410827103.9A patent/CN118955401A/zh active Pending
- 2019-03-19 US US16/358,642 patent/US10851067B2/en active Active
- 2019-03-19 CN CN201980033266.7A patent/CN112771039A/zh active Pending
- 2019-03-19 JP JP2020551340A patent/JP7757036B2/ja active Active
- 2019-03-19 KR KR1020257032902A patent/KR20250150168A/ko active Pending
- 2019-03-19 CA CA3093976A patent/CA3093976A1/en active Pending
- 2019-03-19 KR KR1020207029659A patent/KR102731128B1/ko active Active
- 2019-03-19 KR KR1020247037753A patent/KR102868652B1/ko active Active
- 2019-03-19 EP EP19772264.8A patent/EP3768677A4/en active Pending
- 2019-03-19 MX MX2020009693A patent/MX2020009693A/es unknown
- 2019-03-19 CN CN202410840828.1A patent/CN118955403A/zh active Pending
- 2019-03-19 WO PCT/US2019/023039 patent/WO2019183148A1/en not_active Ceased
-
2020
- 2020-09-17 MX MX2023001153A patent/MX2023001153A/es unknown
- 2020-10-22 US US17/077,068 patent/US11261162B2/en active Active
-
2022
- 2022-01-07 US US17/570,536 patent/US11724990B2/en active Active
-
2023
- 2023-06-20 US US18/338,096 patent/US12286408B2/en active Active
- 2023-08-21 ZA ZA2023/08070A patent/ZA202308070B/en unknown
- 2023-11-16 JP JP2023195267A patent/JP2024026104A/ja active Pending
- 2023-11-17 AU AU2023266373A patent/AU2023266373B2/en active Active
-
2024
- 2024-04-17 AU AU2024202496A patent/AU2024202496B2/en active Active
-
2025
- 2025-03-29 US US19/094,862 patent/US20260062389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12286408B2 (en) | KV7 channel activators compositions and methods of use | |
| TW201825484A (zh) | 作為TARP-γ8依賴性AMPA受體拮抗劑之6-((S)-1-{1-[5-(2-羥基-乙氧基)-吡啶-2-基]-1H-吡唑-3-基}-乙基)-3H-1,3-苯并噻唑-2-酮 | |
| JP2025507543A (ja) | Ｋｖ７チャネル活性化剤としてのピラゾリル化合物 | |
| EP4482487A1 (en) | Pyrazolyl compounds as kv7 channel activators | |
| WO2023164536A1 (en) | Pyrazolyl compounds as kv7 channel activators | |
| HK40119318A (en) | Kv7 channel activators compositions and methods of use | |
| HK40118422A (en) | Kv7 channel activators compositions and methods of use | |
| HK40119317A (en) | Kv7 channel activators compositions and methods of use | |
| HK40119631A (en) | Kv7 channel activators compositions and methods of use | |
| HK40120047A (en) | Kv7 channel activators compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220928 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240712 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION Effective date: 20240916 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260106 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260428 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260428 |